| 摘要 |
The disclosure is directed to compositions, kits, and methods using a blocking agent that is Protein A, Protein A/G, Protein G, Protein L, or active portions thereof. The blocking agent reduces analyte-independent antibody interactions in an immunoassay, such as an ELISA, and therefore minimizes false positive results. |
